Does dapagliflozin improve clinical events and symptoms in patients with preserved or mildly reduced ejection fraction heart failure irrespective of baseline atrial fibrillation type?
Dapagliflozin provides consistent clinical and symptomatic benefits in heart failure with preserved or mildly reduced ejection fraction, regardless of the type of baseline atrial fibrillation.
In DELIVER, the beneficial effects of dapagliflozin compared with placebo on clinical events and symptoms were consistent, irrespective of type of AF at baseline. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. DELIVER; NCT03619213).
Butt et al. (Sat,) studied this question.